How Sweet It Isn’t: Genentech Investors Want Higher Roche Bid
This article was originally published in The Pink Sheet Daily
Executive Summary
New survey suggests Genentech’s minority shareholders won’t tender at the $86.50 price.
You may also be interested in...
Roche Checks Wallet As Important Avastin Trial Flops
After months of anticipation, Roche announced the results of a closely watched clinical trial showing that its Avastin (bevacizumab) medication failed to prevent the recurrence of early-stage colon cancer in patients who underwent surgery
Roche Checks Wallet As Important Avastin Trial Flops
After months of anticipation, Roche announced the results of a closely watched clinical trial showing that its Avastin (bevacizumab) medication failed to prevent the recurrence of early-stage colon cancer in patients who underwent surgery
Roche Checks Wallet As Important Avastin Trial Flops
Did Roche overpay for Genentech? Closely watched adjuvant trial for colon cancer fails to meet primary endpoint.